About CureMetrix
CureMetrix is a healthcare AI company dedicated to advancing medical image analysis technology to improve disease detection and survival rates globally. The company leverages artificial intelligence and deep learning to develop next-generation solutions, primarily focusing on mammography as a precision tool for radiologists.
Their technology, including products like cmAssist® and cmAngio®, aims to equip radiologists with objective, data-driven insights to enhance the accuracy of detecting and classifying anomalies in medical images. cmAssist®, an AI-based computer-aided detection (CAD) system, has demonstrated an average improvement of 27% in cancer detection without increasing recalls, working effectively across various breast densities and lesion types. Additionally, cmAngio® is the first and only FDA-cleared AI software designed to detect and localize breast arterial calcifications (BAC) on screening mammograms, which can serve as a marker for cardiovascular risk.
CureMetrix is committed to developing highly efficacious products that seamlessly integrate into existing clinical workflows, minimizing additional steps for healthcare professionals and patients. They have built a robust platform by partnering with radiologists and institutions worldwide to collect and train their algorithms on over 5 million images, with a broader vision to apply AI to improve outcomes for various conditions, including heart and kidney disease.
Focus Areas
Business Intelligence
| Key Investors | Arben Ventures, UnitLeader, XB Ventures, EvoNexus, Analytics Ventures, Keshif Ventures, La Costa Investment Group, Bold Brain Ventures |
| Partnerships | SimonMed Imaging, Therapixel (MammoScreen), Volpara Health (Lunit), Novarad, Rezolut Imaging, Halo Dx, Ambra Health, American Heart Association Center for Health Technology & Innovation |
| Technology | AI-based products, deep learning, scientific algorithm, cloud-based SaaS solution, DICOM and HIPAA compliant, analyzes full-field digital mammography (FFDM) and digital breast tomosynthesis (DBT) |
| FDA Clearances | 2 cleared products (estimated) |
What Physicians Need to Know
For physicians, CureMetrix's solutions offer several key advantages. The AI-driven CAD (cmAssist) significantly reduces false positives and unnecessary recalls (up to 69% fewer false markings), allowing radiologists to focus on truly suspicious findings and improve diagnostic accuracy. The neuScoreu2122 provides a quantitative measure of suspiciousness, aiding in consistent interpretation. cmTriage streamlines workflow by prioritizing cases, and cmDensity automates breast density classification, enhancing efficiency and consistency in reporting. Furthermore, cmAngio empowers radiologists to identify cardiovascular risk factors (BAC) from routine mammograms, enabling proactive patient management and referrals for heart health evaluation, maximizing the clinical value of a single exam. The cloud-based, secure, and DICOM-compliant nature ensures easy integration into existing workflows without requiring on-site hardware.
CureMetrix solutions are delivered as cloud-based Software-as-a-Service (SaaS), utilizing AWS services, ensuring quick and easy installation (often in less than an hour) without the need for on-site hardware. They are DICOM compliant and designed to work seamlessly with multiple image acquisition manufacturers (e.g., Hologic, GE Healthcare) and any DICOM-compliant viewer, integrating into existing PACS workflows. Patient Health Information (PHI) remains secure within the facility, as images are anonymized by an edge client before being sent to the cloud for AI analysis. CureMetrix also engages in strategic partnerships, such as with Therapixel Inc. (MammoScreen) and Novarad, to offer comprehensive AI imaging solutions and expand access to their technology.
What the Web Says
CureMetrix develops AI-enhanced mammography software designed to improve breast cancer detection and reduce false positives. Their technology, including cmAngio, is FDA-cleared and aims to provide radiologists with advanced tools for more accurate and efficient mammogram evaluations. The company's mission focuses on improving clinical and financial outcomes for imaging centers and healthcare systems, as well as increasing patient assurance. While specific employer reviews for CureMetrix were not readily available on the searched platforms, product reviews highlight the potential of their AI in enhancing diagnostic accuracy.
Overall: PositiveStrengths
- Potential to decrease false-positive rates in mammograms, reducing unnecessary follow-up procedures and patient anxiety.
- Aids radiologists in detecting subtle or hard-to-see abnormalities in breast images.
- Can potentially reduce false positive marks by up to 69% when used by a radiologist.
- FDA-cleared AI software for mammography, including detection of breast arterial calcifications (BAC).
- Integrates into existing workflows and provides expanded clinical insight.
- Offers a precision tool for mammography that equips radiologists with data-driven answers.
Limitations
- No specific employer reviews were found on G2, Glassdoor, Capterra, or Reddit for CureMetrix.
- One of the significant challenges facing AI adoption in healthcare is trust from both doctors and patients.
- Concerns among some radiologists that AI algorithms could replace their clinical expertise.
- Further clinical validation may be needed for some AI models in breast cancer detection.
Based on reviews from: Slashdot, SourceForge, G2, Docpanel, CureMetrix (Official Website), Reddit, PitchBook
Last updated: 2026-07-18
Videos
News, demos, and interviews about CureMetrix.
Videos load interactively. If none appear, search YouTube for CureMetrix →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded CureMetrix.
Comparisons
Related Companies
QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]
Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]